Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Visual pathway glioma
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 36 for your search:
Start Over
Acupressure in Controlling Nausea in Young Patients with Central Nervous System or Solid Tumors Receiving Nausea-Inducing Chemotherapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 4 to 18
Trial IDs: SCUSF 1202, NCI-2011-02668, ACCL1032, CDR0000699766, COG-ACCL1032, NCT01346267
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Modafinil in Treating Children with Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 to 19
Trial IDs: ACCL0922, NCI-2011-02594, CDR0000702733, SCUSF 0901, NCT01381718
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 22
Trial IDs: ACNS1022, NCI-2012-00703, CDR0000728296, COG-ACNS1022, NCT01553149
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 18
Trial IDs: CHOA2725-14, NCI-2015-00181, IRB00074563, NCT02343224
Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 201604002, NCI-2016-00549, NCT02689336
Pomalidomide in Treating Younger Patients with Recurrent, Progressive or Refractory Central Nervous System Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 20
Trial IDs: PBTC-043, NCI-2014-02182, CC-4047-PBTC-043, PPBTC-043_R04PAPP01, NCT02415153
Ramucirumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1416, NCI-2015-00744, NCT02564198
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: NLG2105, NCI-2015-01872, NCT02502708
iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
18F-FDG PET or 1H-MRSI in Assessing Tumor Activity in Younger Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic, Natural history/Epidemiology
Age: 1 to 21
Trial IDs: 03-C-0278, NCI-2013-02042, 030278, NCT00070512, NCI-03-C-0278, NCT00067821
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Status: Active
Phase: No phase specified
Type: Tissue collection/Repository
Age: Pediatric
Trial IDs: ACNS02B3, NCI-2009-00334, CDR0000352347, COG-ACNS02B3, NCT00919750
Collecting and Storing Tissue From Young Patients With Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 21 and under
Trial IDs: ABTR04B1, NCI-2009-00326, CDR0000478867, COG-ABTR04B1, NCT00898755
Neutropenic Diet in Preventing Infections in Younger Patients Receiving Chemotherapy
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 1 to 21
Trial IDs: 06-08-367, NCI-2014-01519, NCI-2014-01460, NCT00726934
DSC-MRI with Ferumoxytol and DCE-MRI with Gadolinium in Imaging Vascular Properties in Younger Patients with Brain Tumors
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 18 and under
Trial IDs: IRB00005405, NCI-2015-00227, 1562, 2864, 813, SOL-09064-LX, NCT00978562
Informed Consent to Enroll Younger Patients with Newly Diagnosed Cancer in the Childhood Cancer Research Network
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and under
Trial IDs: ACCRN07, NCI-2009-00331, CDR0000069496, 10-C-0111, NCT01117168
Bevacizumab in Treating Brain Injury Caused by Radiation Therapy in Younger Patients with Central Nervous System Tumors
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 1 to 25
Trial IDs: 10-0418, NCI-2016-00272, NCT01201850
Biologic and Pathophysiologic Effects of Radiation Therapy in Younger Patients with Central Nervous System Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and under
Trial IDs: 06-C-0219, NCI-2013-02056, 060219, P6810, NCT01445288
Neurobehavioral Functioning in Patients with Chronic Illness
Status: Enrolling by invitation
Phase: No phase specified
Type: Natural history/Epidemiology
Age: Any age
Trial IDs: 07-C-0110, NCI-2013-02060, 070110, P06098, NCT01445314
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid, Central Nervous System, or Germ Cell Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Start Over